| Stereochemistry | RACEMIC |
| Molecular Formula | C13H11N3OS |
| Molecular Weight | 257.311 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][S+](CC1=CC=CC=N1)C2=NC3=CC=CC=C3N2
InChI
InChIKey=HBDKFZNDMVLSHM-UHFFFAOYSA-N
InChI=1S/C13H11N3OS/c17-18(9-10-5-3-4-8-14-10)13-15-11-6-1-2-7-12(11)16-13/h1-8H,9H2,(H,15,16)
| Molecular Formula | C13H11N3OS |
| Molecular Weight | 257.311 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Timoprazole is a substituted benzimidazole patented by Aktiebolag Hassle as an antisecretory agent that inhibits gastric acid secretion by interference with (H+-K+)-ATPase. Timoprazole given orally was found to be cytoprotective for the stomach when given 30 min prior to a challenge to boiling water, ethanol, or HCl. Timoprazole also prevented necrosis of the mucosa and acute ulcerations induced by alcohol in the rat fundus, as evaluated by histopathology.
